Molecular mechanism study showed that elafibranor can promote lipid metabolism by upregulating genes such as fatty acid-binding protein 4 (Fabp4) and acyl-CoA oxidase 1 (Acox1), and inhibit liver inflammation and liver fibrosis, evidenced by inhibited expression of genes such as C-C motif chemokine ligand 6 (CCL6), TGF-β1, type one collagen alpha 1 (Col-1A1), and tissue inhibitor of metalloproteinases 1 (TIMP-1) [23]. The gene discussed is FABP4; the disease is Hepatic fibrosis.